Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma

A phase I trial to assess the value of r

A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (r-MetHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL)

✍ G. M. Smith; J. A. Child; M. H. Cullen; N. P. Bailey; C. M. Woodruffe; J. Fletch 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 571 KB

In a multi-centre phase I study we investigated the possibility of reducing the interval between courses of standard CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m', vincristine 2 mgs day 1, and prednisolone 40mglm' days 1-8) from 21 days to 15 days and then 10 days using granulocyte colony s